A Study Of Airway Mycobiome In Inflammation And Chronic Infections In Bronchiectasis

Overview

About this study

The purpose of this study is to investigate the relationship between inflammatory endotypes of NCFB and the airway mycobiome. We hypothesize that patients with EB, defined by an absolute eosinophil count >300 cells/uL at the time of respiratory sample collection, have a higher relative abundance of molds in their airways compared to NCFB patients with other inflammatory endotypes.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18 or greater.

  • Confirmed diagnosis of bronchiectasis.

  • Appointment scheduled on Gonda 18 South.

 

Exclusion Criteria: 

  • Bronchiectasis known due to Cystic Fibrosis.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/6/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Amjad Kanj, M.D., M.P.H.

Open for enrollment

Contact information:

Shannon Daley

5072930637

daley.shannon@mayo.edu

More information

Publications

Publications are currently not available